New non-invasive test to detect bladder cancer could spare patients cystoscopy

February 1, 2017
New non-invasive test to detect bladder cancer could spare patients cystoscopy
Credit: University College London

A new test for bladder cancer could enable GPs to test a urine sample and spare patients the discomfort of a cystoscopy in hospital, according to UCL research published today in Clinical Epigenetics.

The , called UroMark, has been developed by UCL researchers and uses cutting edge genomic sequencing to detect abnormal cancer DNA in a . The research team, led by Professor John Kelly and Dr Andy Feber (UCL Cancer Institute), identified a panel of DNA alterations which are highly specific to and found that when used on DNA from , UroMark detected bladder cancer with a high degree of accuracy (98% of cases), equivalent to a cystoscopy, currently the clinical gold standard.

The study was carried out on 300 and the UK Medical Research Council has awarded £1.42 million for two larger trials which are currently underway across 32 hospitals. The trials will confirm the accuracy of UroMark before it becomes widely available for clinical use.

Approximately 11,000 people are diagnosed with bladder cancer each year in the UK. For most people, an early sign of bladder cancer is blood in their urine (haematuria), but many patients experience symptoms such as recurrent infection; and the urgency and irritation to urinate.

Normally, patients with blood in their urine are sent to hospital for tests, which include passing an instrument along the water pipe or urethra to inspect the bladder (cystoscopy). The will avoid the need for cystoscopy for many patients and can be tested by GPs if cancer is suspected.

Professor John Kelly said: "We have good evidence that patients, particularly females, are diagnosed late with bladder cancer and often patients visit a GP several times with symptoms prior to detection. Having the UroMark test available to GPs will mean that patients can be tested at an early stage to rule out bladder cancer."

The team anticipate that UroMark will reduce the costs of having to refer patients to hospital. In the UK around 110,000 cystoscopies are performed each year, at a cost to the NHS in the region of £55.39 million.

Explore further: What you need to know about bladder cancer

More information: Andrew Feber et al. UroMark—a urinary biomarker assay for the detection of bladder cancer, Clinical Epigenetics (2017). DOI: 10.1186/s13148-016-0303-5

Related Stories

What you need to know about bladder cancer

July 26, 2016
Bladder cancer accounts for 5 percent of all new cancer diagnoses in the U.S. with nearly 77,000 new cases annually; 1,100 people died of bladder cancer in Kentucky between 2010 and 2014.

Invisible blood in urine may indicate bladder cancer

August 31, 2014
New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians.

Bladder cancer clinical trial opens to patients

October 13, 2016
A bladder cancer clinical trial led by scientists at the University of Sheffield and funded by Yorkshire Cancer Research is now recruiting patients.

'Scent device' could help detect bladder cancer

July 8, 2013
Researchers from the University of Liverpool and University of the West of England, (UWE Bristol), have built a device that can read odours in urine to help diagnose patients with early signs of bladder cancer.

Urine test could help detect aggressive bladder cancer

November 29, 2013
A simple urine test could distinguish between aggressive and less aggressive bladder cancers according to a new Cancer Research UK study published in the British Journal of Cancer.

Highly reliable urine test developed for the early detection of a common type of bladder cancer

October 21, 2015
A panel of five biomarkers that can detect the presence of transitional cell bladder carcinoma in urine with 100 per cent specificity has been developed by A*STAR researchers. The noninvasive technique could be developed ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.